NORWALK, Conn., March 5, 2015 /PRNewswire/ -- UBM Medica US announces that OncoTherapy Network, a leading online community to help oncologists and other clinicians gain a better understanding of the newest information available regarding the use of targeted therapies and immunotherapies, highlights special coverage of kidney cancer.
March is National Kidney Cancer Awareness Month, and there are very few effective adjuvant treatment options for renal cell carcinoma (RCC) patients. Aside from surgical resection—which can be curative—30% to 40% of intermediate- and high-risk early-stage RCC patients are at risk for relapse within five years. This is why research in this area is so important. As many studies continue to identify biomarkers, along with targeted therapy and immunotherapy use in all RCC patients, there's hope of promising new treatment options in the near future.
Some of areas researchers are focusing on when it comes to kidney cancer treatment options and biomarker research:
- Sorafenib nor Sunitinib Effective As Adjuvant Kidney Cancer Therapy: Neither sunitinib nor sorafenib reduced disease recurrence in patients with locally advanced renal cell carcinoma (RCC) when these agents were given to patients as adjuvant therapy, according to the results of a new study.
- Lenvatinib for Renal Cell Carcinoma Meets Primary Endpoint in Phase II trial: Japanese drug maker Eisai announced that the multiple kinase inhibitor lenvatinib, alone and in combination with everolimus, has been shown to prolong progression-free survival (PFS) in patients with unresectable advanced or metastatic renal cell carcinoma (mRCC).
- Potential Therapeutic Target for Kidney Cancer: Researchers have uncovered a novel way to potentially target clear cell renal cell carcinoma (ccRCC), a predominantly incurable disease for which patients have limited treatment options.
About UBM Medica US
Addressing today's healthcare information needs, UBM Medica US, delivers strategic, integrated communications solutions and comprehensive reach -- online, in print, via custom programs and live events. Improving the effectiveness of healthcare through information and education, UBM Medica US provides unbiased clinical, practical, and business information for physicians, providers and payers resulting in improved quality of care for patients around the world. Through journals, magazines, online communities, live and digital events, and other valuable resources, UBM Medica US also delivers comprehensive communication solutions for the pharmaceutical and related industries. Online communities include CancerNetwork.com, ConsultantLive.com, DiagnosticImaging.com, RheumatologyNetwork.com, OBGYN.net, PhysiciansPractice.com, PsychiatricTimes.com and SearchMedica.com. UBM Medica US is part of UBM Connect which, through a range of aligned interactive environments, both physical and digital – increases business effectiveness for both customers and audiences through meaningful experiences, knowledge and connections. Headquartered in New York, UBM Connect brings together UBM's healthcare business, UBM Medica US; UBM Canon's advanced design and manufacturing event, online and print brands; UBM Connect New York's catering, cruise shipping, customer management, and fine, specialty and custom chemical communities; and UBM Mexico's concrete show. For more information, visit www.UBMMedicaUS.com.
About UBM plc
UBM plc is a global events-led marketing services and communications company. We help businesses do business, bringing the world's buyers and sellers together at events and online, as well as producing and distributing news and specialist content. Our 5,500 staff in more than 30 countries are organized into expert teams which serve commercial and professional communities, helping them to do business and their markets to work effectively and efficiently.
For more information, go to www.ubm.com; follow us on Twitter at @UBM_plc to get the latest UBM corporate news.
Media contact:
Jason J. Golden
Content Marketing Manager
203-523-7040
Logo - http://photos.prnewswire.com/prnh/20150305/179801LOGO
SOURCE UBM Medica US
Related Links
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article